Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients

Landre, Thierry; Maillard, E.; Taleb, Chérifa; Ghebriou, Djamel; Guetz, G. Des; Zelek, Laurent; Aparicio, Thomas

doi:10.1007/s00384-018-3053-3

Cited by 16 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis included 10 studies and 1,652 older patients and had a cut-off of 70 or 75 years [20]. The addition of bevacizumab to FPs statistically improved both overall survival (OS) and PFS (HR 0.78, 95% CI 0.63-0.96 and HR 0.55, 95% CI 0.44-0.67, respectively).…”

Section: Single-agent or Doublet Chemotherapy ± Bevacizumab In Older ...mentioning

confidence: 99%

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

Gilabert

Ries

Chanez

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Section: Single-agent or Doublet Chemotherapy ± Bevacizumab In Older ...mentioning

confidence: 99%

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

Gilabert

Ries

Chanez

et al. 2020

Journal of Geriatric Oncology

View full text Add to dashboard Cite

“…A meta-analysis on individual data confirms that age is a factor with an impact in PFS and that adding bevacizumab improves PFS in patients over 70 years [54]. Another meta-analysis which specifically studied the population over 70 years, including AVEX [36], PRODIGE 20 [51], and subgroup analysis of the AGITG-MAX trial [55] and AVF2192g studies [56] reported that adding bevacizumab to chemotherapy significantly improved PFS and OS compared to chemotherapy alone [57] (Table 5).…”

Section: Bevacizumab 1 St Linementioning

confidence: 91%

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

Aparicio

Canouï‐Poitrine

Caillet

et al. 2020

Digestive and Liver Disease

Self Cite

View full text Add to dashboard Cite

“…Conversely, oxaliplatin-based chemotherapy showed no significant differences for PFS or OS. In elderly patients, the combination of bevacizumab with fluoropyrimidine was found to be more effective for OS and PFS than the addition of a third agent, such as irinotecan or oxaliplatin [21].…”

Section: Plos Onementioning

confidence: 99%

Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer remains one of the most frequent malignancies (third place at both genders) worldwide in the last decade, owing to significant changes in modern dietary habits. Approximately half of the patients develop metastases during the course of their disease. The available therapeutic armamentarium is constantly evolving, raising questions regarding the best approach for improving survival. Bevacizumab remains one of the most widely used therapies for treating metastatic colorectal cancer and can be used after progression. This study aimed to identify the best chemotherapy partner for bevacizumab after progression. We performed a retrospective analysis of patients with metastatic colorectal cancer who were treated with bevacizumab as first- and second-line chemotherapy. Data were collected for 151 patients, 40 of whom were treated with double-dose bevacizumab after the first progression. The two standard chemotherapy regimens combined with bevacizumab were FOLFIRI/CAPIRI and FOLFOX4/CAPEOX. The initiation of first-line treatment with irinotecan-based chemotherapy improved progression-free survival and time to treatment failure but not overall survival. After the first progression, retreatment with the same regimen as that used in the induction phase was the best approach for improving overall survival (median overall survival: 46.5 vs. 27.0 months for the same vs. switched strategy, respectively). No correlations were observed between the dose intensity of irinotecan, oxaliplatin, 5-fluorouracil, or bevacizumab and the overall survival, progression-free survival in the first-/second-line treatment, and time to treatment failure. Interaction between an irinotecan-based regimen as a second-line treatment and double-dose bevacizumab after progression was associated with an improved overall survival (p = 0.06). Initiating systemic treatment with an irinotecan-based regimen in combination with bevacizumab improved the progression-free survival in the first-line treatment and time to treatment failure. In terms of overall survival, bevacizumab treatment after the first progression is better partnered with the same regimen as that used in the induction phase.

show abstract

Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients

Abstract: In previously untreated elderly patients with MCRC, the addition of bevacizumab to fluoropyrimidin appears more effective in terms of OS or PFS than the addition of oxaliplatin or irinotecan.

Cited by 16 publications

References 21 publications

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis

Contact Info

Product

Resources

About